Finally, RIP2 is able to activate the nonclassical NF-κB pathway in human Burkitt lymphoma cells, which may be one of the mechanisms by which RIP2 affects the prognosis of DLBCL patients [28]. The gene discussed is NFKB1; the disease is diffuse large B-cell lymphoma.